Suchergebnisse - "Drug Therapy, Combination"

PubPharm (710)

71

The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study

in: Diabetes & Metabolism Journal | 2023

von Jun Sung Moon | Il Rae Park | Sang Soo Kim | +8

72

Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension

in: Diabetes & Metabolism Journal | 2023

von Jun Sung Moon | Il Rae Park | Hae Jin Kim | +12

73

Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors

enthalten in: Journal for immunotherapy of cancer | 2023

von Lemech, C. | Dredge, K. | Bampton, D. | +11

74

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma

enthalten in: Journal for immunotherapy of cancer | 2022

von Rini, B. | Signoretti, S. | Choueiri, T. | +11

75

Identification of natural product 3, 5-diiodotyrosine as APOBEC3B inhibitor to prevent somatic mutation accumulation and cancer progression

enthalten in: Journal for immunotherapy of cancer | 2022

von Chen, C. | Sui, X. | Ning, H. | +16

76

First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors

enthalten in: Journal for immunotherapy of cancer | 2022

von Hamid, O. | Chiappori, A. | Thompson, J. | +15

77

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

enthalten in: Journal for immunotherapy of cancer | 2022

von Casarrubios, M. | Provencio, M. | Nadal, E. | +22

78

Onset of efficacy and adverse events during Cenobamate titration period

enthalten in: Acta neurologica Scandinavica | 2022

von Steinhoff, B. | Ben-Menachem, E. | Brandt, C. | +4

79

Elicitation of stem-like CD8+ T cell responses via lymph node-targeted chemoimmunotherapy evokes systemic tumor control

enthalten in: Journal for immunotherapy of cancer | 2022

von Manspeaker, M. | O'Melia, M. | Thomas, S.

80

„Patient-reported outcomes“

enthalten in: Die Onkologie | 2022

von Hilser, T. | Darr, C. | Grünwald, V.